AIP
MRKR icon

Ameritas Investment Partners’s Marker Therapeutics MRKR Stock Holding History

Ameritas Investment Partners’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-239
Closed -$5K – 3165
2021
Q1 		$5K Hold
239
– – ﹤0.01% 3004
2020
Q4 		$3K Hold
239
– – ﹤0.01% 3026
2020
Q3 		$4K Hold
239
– – ﹤0.01% 3013
2020
Q2 		$5K Hold
239
– – ﹤0.01% 2959
2020
Q1 		$5K Hold
239
– – ﹤0.01% 2818
2019
Q4 		$7K Hold
239
– – ﹤0.01% 2840
2019
Q3 		$12K Hold
239
– – ﹤0.01% 2664
2019
Q2 		$19K Buy
+239
New +$14.2K ﹤0.01% 2473

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Investment Partners's MRKR Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 239 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in MRKR in Q2 2019 and held it in 8 quarters. The position peaked at $19K in Q2 2019. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 239 Marker Therapeutics shares in Q2 2021, an estimated $5K.
  • Ameritas Investment Partners first reported a position in Marker Therapeutics in Q2 2019 and held it in 8 quarters.
  • Ameritas Investment Partners's Marker Therapeutics position peaked at $19K in Q2 2019.
  • 74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.